This Healthcare Stock Trades at a Richer Valuation Than Nvidia. Could It Also Deliver Bigger Long-Term Returns?

The article argues Intuitive Surgical may be more attractive than Nvidia at current valuations, citing a 50x P/E versus a nearly 70% five-year average premium and continued double-digit procedure growth. Da Vinci procedures rose 17% year over year in Q1 2026, while the installed robot base increased 12%, supporting recurring, annuity-like revenue from services, instruments, and accessories. It also highlights FDA clearance in late 2025 for additional SP system uses, expanding the long-term addressable market.

Analysis

The market is still valuing AI as a pure hardware cycle, but the more durable moat may actually sit with ISRG’s installed base economics. Once a robot is in place, the earnings stream shifts from lumpy capital sales to recurring procedural consumption, which makes the business less sensitive to macro capex pauses than most med-tech peers and far less exposed to a single product-generation reset than semis. That creates a different compounding profile: slower headline growth than NVDA at peaks, but better durability through downturns and higher visibility on medium-term cash conversion.

The key second-order effect is that robotics penetration can expand even if procedure mix only grows modestly, because hospital economics improve as utilization rises. That means the upside is not just more robots sold, but a rising attach rate on instruments, servicing, and training as utilization deepens across the fleet. In practice, the most important driver over the next 12-24 months is likely not the next robot launch, but expansion of approved procedure categories, which can re-rate the stock without requiring a step-change in unit shipments.

The contrarian takeaway is that the valuation debate may be misframed: NVDA is being priced like a beneficiary of a multi-year platform shift, while ISRG is being priced as if its runway is mature despite a much longer-duration adoption curve. The real risk to ISRG is not near-term demand, but reimbursement pressure or slower-than-expected procedure conversion if hospitals delay purchases amid budget scrutiny. For NVDA, the risk is faster compression in pricing power if supply normalizes or a credible competitor narrows performance gaps, which could hit sentiment within quarters rather than years.

Key Decisions for Investors

• Long ISRG vs short NVDA as a 6-12 month relative-value pair: ISRG has lower technological obsolescence risk and a recurring revenue mix that should support multiple durability if AI capex enthusiasm cools.
• Buy ISRG on any 5-8% pullback over the next 1-2 months; target a re-rating toward its historical P/E range over 12 months if procedure growth stays mid-teens and new indications keep expanding.
• For upside convexity, consider ISRG call spreads 12-18 months out rather than outright shares: the market is underpricing procedure expansion, but reimbursement or hospital-budget noise can cap near-term multiple expansion.
• Trim/hedge NVDA on strength into AI infrastructure headlines: use a 3-6 month horizon, because the main risk is not business collapse but multiple compression if the market shifts from scarcity to competition.
• Watch for FDA/label-expansion announcements as the catalyst to add to ISRG; these are the cleanest triggers for estimate revisions and typically matter more than quarterly hardware unit prints.